Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment

British Journal of Clinical Pharmacology

Volumn 72, Issue 5, 2011, Pages 798-805

  Teichert, Martina ^a,b   Visser, Loes E ^a   Uitterlinden, Andre G ^a   Hofman, Albert ^a   Buhre, Peter J ^c   Straus, Sabine ^a,d   De Smet, Peter A G M ^b,e   Stricker, Bruno Hch ^a,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Scientific Institute Dutch Pharmacists   (Netherlands)

^c STAR Medical Diagnostic Center   (Netherlands)

^d MEDICINES EVALUATION BOARD   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Drug Safety Unit   (Netherlands)

Author keywords

Acenocoumarol; Fluvoxamine; Selective serotonin re uptake inhibitors; Venlafaxine

Indexed keywords

ACENOCOUMAROL; CITALOPRAM; CYTOCHROME P450 2C9; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERANTICOAGULATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; WILD TYPE;

ACENOCOUMAROL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIDEPRESSIVE AGENTS; BLOOD COAGULATION; COHORT STUDIES; CYCLOHEXANOLS; DRUG INTERACTIONS; FLUVOXAMINE; HEMORRHAGE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 80053919302     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04004.x     Document Type: Article

References (45)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 3 (Suppl.): 204S-233S.
2. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Mueller CR, Wienker TF, Oldenburg J. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-9.
3. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteren P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
4. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
5. Carlquist JF, Horne B, Muhlestein J, Lappé D, Whiting B, Kolek M, Clarke JL, James BC, Anderson JL. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22: 191-7.
6. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006; 79: 291-302.
7. Oldenburg J, Bevans C, Fergin A, Geisen C, Müller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-8.
8. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Gen 2009; 18: 3758-68.
9. Qazim B, Stöllberger C, Krugluger W, Dossenbach-Glaninger A, Finsterer J. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Haemost 2009; 28: 211-4.
10. van der Hooft C, Dieleman JP, Siemes C, Aarnoudse ALHJ, Verhamme KC, Stricker BHC, Sturkenboom MC. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 2008; 17: 365-71.
11. Leendertse A, Egberts A, Stoker L, Bemt van der P. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-6.
12. de Abajo F, Rodríguez L, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1990; 19: 1106-9.
13. Oksbjerg Dalton S, Johanson C, Meelmkjaer L, Norgard B, Sorensen H, Olsen J. Use of selective serotonin reuptake inhibitors and risk of upper astrointestinal tract bleeding. Arch Intern Med 2003; 163: 59-64.
14. Walraven van C, Mamdani M, Wells P, Williams J. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 319: 655-8.
15. Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, Crowell MD, Keshavarzian A, Jones MP. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23: 937-44.
16. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119: 113-6.
17. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, Egberts ACG. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367-70.
18. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie. Informatorium, Pharmacokinetics with Proton Pump Inhibitors. The Hague: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 2008.
19. Yap K, Low S. Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Med J 1999; 40: 480-2.
20. Dent L, Orrock M. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997; 17: 170-2.
21. Woolfrey S, Gammack N, Dewar M, Brown P. Fluoxetine-warfarin interaction. BMJ 1993; 307: 241.
22. Limke K, Shelton A, Elliott E. Fluvoxamine interaction with warfarin. Ann Pharmacother 2002; 36: 1890-2.
23. Optamy L, Delaney J, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81.
24. Kurdyak P, Juurlink D, Kopp A, Herrmann N, Mamdani M. Antidepressants, Warfarin, and the Risk of Hemorrhage. J Clin Psychopharmacol 2005; 25: 561-5.
25. Schalekamp T, Klungel JH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180-5.
26. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-22.
27. Hofman A, Breteler M, van Duijn C, Krestin G, Pols H, Stricker B, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007; 22: 819-29.
28. Hofman A, Breteler M, Van Duijn C, Janssen H, Krestin G, Kuipers E, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009; 24: 553-72.
29. World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo: World Health Organization Collaborating Centre for Drug Statistics Methodology, 2004.
30. Flockhart D, O'Kane D, Williams M, Watson M, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10: 139-50.
31. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
32. Aspeloff G, Wilner K, Gerber N, Tremaine L. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997; 32 (Suppl. 1): 37-42.
33. Visser LE, van Schaik RHN, van Vliet M, Trienekens PH, De Smet PAGM, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005; 77: 479-85.
34. Teichert M, van Noord C, Uitterlinden A, Hofman A, Buhre P, De Smet P, Straus S, Stricker BH, Visser LE. Proton pump inhibitors and the risk on hyperanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 2011; 153: 379-85.
35. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RHN, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. A genome-wide association study of acenocoumarol maintenance dosage. Human Molecular Genetics 2009; 18: 3758-68.
36. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, Schabath MB, Couper DJ, Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, Uitterlinden AG, Hofman A, Punjabi NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert SR, Lumley T, Stricker BH, O'Connor GT, London SJ. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42: 45-52.
37. Andersen P, Gill R. Cox's regression model for counting processes: a large sample study. Ann Statist 1982; 10: 110-2.
38. Stricker B, Steijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010; 25: 245-51.
39. Ford M, Anderson M, Rindone J, Jaskar D. Lack of effect of fluoxetine on the hypothrombinemic response of warfarin. J Clin Psychopharmacol 1997; 17: 110-2.
40. Priskorn M, Sidhu J, Larsen F, Davis J, Khan A, Rolan P. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44: 199-202.
41. Schmider J, Greenblatt D, von Moltke L, Karsov D, Shader R. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1996; 44: 495-8.
42. Duncan D, Sayal K, McConnell H, Taylor D. Antidepressant interactions with warfarin. Int Clin Psychopharmacol 1998; 13: 87-94.
43. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44: 1227-12246.
44. Kurdyak P, Juurlink D, Kopp A, Herrmann N, Mamdani N. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005; 26: 561-4.
45. Optarny L, Delaney J, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66: 76-81.